Epidemiology and Management of Cutaneous T-Cell Lymphoma at Hospital México, Costa Rica.
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Lymph Node Cancer, Cutaneous, T-cell Lymphoma. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Costa Rica
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Epidemiological Profile and Therapeutic Management of Patients Diagnosed With Cutaneous T-cell Lymphoma Evaluated in the Dermatology Department of Hospital México During the Period From 2019 to 2025.
Overview
Adult patients (≥18 years) with confirmed cutaneous T-cell lymphoma evaluated at Hospital México between 2019 and 2025 will be retrospectively analyzed using EDUS records to describe their epidemiological profile, clinical characteristics, treatments, and outcomes.
Detailed description
This retrospective observational study will analyze adult patients (≥18 years) with a confirmed diagnosis of cutaneous T-cell lymphoma evaluated in the Dermatology Service of Hospital México between January 2019 and December 2025. Data will be obtained from electronic medical records (EDUS), including sociodemographic characteristics, clinical presentation, histopathological and immunohistochemical findings, disease staging, treatment modalities, and clinical outcomes.
Patients must have at least one documented dermatological evaluation and have received treatment, including skin-directed therapies and/or systemic therapies. Records that are incomplete, inconsistent, or lack histopathological confirmation will be excluded.
The study aims to characterize local epidemiological and therapeutic patterns and describe clinical outcomes using descriptive statistical analysis, providing updated real-world evidence to support clinical decision-making and optimize management strategies for cutaneous T-cell lymphoma in a national referral center.
Primary outcome measures
- Characterize the epidemiology [Time frame: 2019-2025]
- Characterize the therapeutic management [Time frame: 2019-2025.]
Secondary outcome measures (7)
- Describe the sociodemographic/epidemiological characteristics [Time frame: 2019-2025]
- Classify the clinical manifestations/clinical subtypes [Time frame: 2019-2025]
- Identify the histopathological/ immunohistochemical findings [Time frame: 2019-2025]
- Analyze the therapeutic management modalities. [Time frame: 2019-2025]
- identify the clinical stage at the time of diagnosis [Time frame: 2019-2025]
- Evaluation of imaging studies and laboratory. [Time frame: 2019-2025]
- Evaluation of clinical course and outcomes. [Time frame: 2019-2025]
Eligibility criteria
Inclusion criteria
- Patients with a confirmed diagnosis of cutaneous T-cell lymphoma, established through clinical, histopathological, and immunohistochemical criteria, documented in EDUS of Hospital México in the Dermatology Service of Hospital México during the period between January 2019 and December 2025.
- Patients aged 18 years or older, of both sexes.
- Patients with at least one dermatological evaluation recorded during the study period.
- Patients who, having a confirmed diagnosis, have received some modality of treatment, including skin-directed therapies (phototherapy, topical treatments, localized radiotherapy) and/or systemic treatments.
Exclusion criteria
- Clinical records that are insufficient or incomplete, preventing adequate diagnostic classification, staging, therapeutic characterization, or evaluation of clinical evolution.
- Patients with a presumptive diagnosis of cutaneous T-cell lymphoma without histopathological confirmation.
- Duplicate or inconsistent records that hinder the correct identification and classification of the patient.
- Patients attended outside the established study period.
- Patients outside the age range.
- Patients who do not belong to the Dermatology Service of Hospital México.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Costa Rica · 1 center
- Hospital México — San José
Identifiers
NCT: NCT07538960 · CEC HM 002-2026